What is the recommended dosing regimen and safety precautions for initiating Wellbutrin (bupropion) in an 18‑year‑old male?

Wellbutrin for 18-Year-Old Male: Dosing and Safety

For an 18-year-old male, initiate bupropion (Wellbutrin) at 150 mg once daily in the morning for 3 days, then increase to 150 mg twice daily (maximum 300 mg/day), with mandatory screening for seizure risk factors, eating disorders, and close monitoring for suicidal ideation during the first 1-2 weeks.

Critical Age-Specific Considerations

At 18 years old, this patient falls into the highest-risk age group for antidepressant-associated suicidality. The FDA black box warning specifically identifies increased risk of suicidal thoughts and behaviors in patients under 25 years of age 1. This is not theoretical—close monitoring within 1-2 weeks of initiation is mandatory, not optional 2, 1.

Standard Dosing Regimen

For Depression (MDD)

• Days 1-3: 150 mg once daily in the morning
• Day 4 onward: 150 mg twice daily (target dose 300 mg/day)
• Maximum dose: 300 mg/day 3, 1

The 2025 American Thoracic Society guideline supports bupropion use in adolescents ages 10-18, with studies using 150-300 mg/day dosing 4. While this patient is technically an adult at 18, the adolescent literature is directly relevant given his age proximity.

For Smoking Cessation

If the indication is smoking cessation:

• Days 1-3: 150 mg once daily
• Days 4-84 (12 weeks): 150 mg twice daily
• Initiate 1-2 weeks before quit date 3, 5, 3

Absolute Contraindications—Screen Before Prescribing

Do not prescribe bupropion if the patient has:

1. Seizure disorder or any seizure risk factors (stroke, brain injury, brain metastases)
2. Current or prior eating disorder (bulimia or anorexia nervosa)—seizure risk is significantly elevated 3, 4, 3, 1
3. Concurrent MAO inhibitor use (requires 14-day washout period) 1
4. Concurrent tamoxifen use 3
5. Closed-angle glaucoma 3

The seizure risk at 300 mg/day is approximately 0.1% (1 in 1,000) when patients are properly screened 6, 7. Never exceed 300 mg/day—higher doses dramatically increase seizure risk.

Mandatory Monitoring Protocol

Week 1-2 (Critical Period)

• In-person or phone contact within 1-2 weeks to assess for:
  • Emergence of suicidal thoughts or behaviors
  • Agitation, irritability, or unusual behavioral changes
  • Worsening depression
  • Anxiety symptoms (bupropion can be anxiogenic, especially at higher doses) 2, 1, 8

Weeks 3-8

• Assess therapeutic response at 6-8 weeks
• If inadequate response, consider switching agents rather than exceeding 300 mg/day 2
• Monitor for common side effects: insomnia, dry mouth, headache, nausea 3, 7

Neuropsychiatric Safety

The 2016 EAGLES trial (n=8,058) found no significant increase in neuropsychiatric adverse events with bupropion compared to nicotine patches or placebo, even in patients with pre-existing psychiatric disorders 3. However, this does not negate the FDA black box warning for young adults—maintain vigilance.

Practical Administration Details

• Swallow tablets whole—do not crush, divide, or chew 1
• Take in the morning (both doses if twice daily)—reduces insomnia risk 1
• May take with or without food 1
• Avoid evening doses—insomnia is the most common side effect 7

Advantages in Young Males

Bupropion has specific benefits for this demographic:

• No sexual dysfunction (unlike SSRIs)—critical for treatment adherence in young males 2, 9
• Weight neutral or slight weight loss (0.5-1.0 kg)—unlike many antidepressants 10
• Minimal anticholinergic effects 11, 12
• No cardiac conduction problems in healthy individuals 11, 12

When to Discontinue

If discontinuing after reaching 300 mg/day, taper to 150 mg once daily before stopping to minimize withdrawal symptoms 1.

Special Populations Requiring Dose Adjustment

• Hepatic impairment (moderate-severe): Maximum 150 mg every other day 1
• Renal impairment (GFR <90): Consider reduced dose/frequency 1

Common Pitfalls to Avoid

1. Exceeding 300 mg/day—dramatically increases seizure risk
2. Missing the eating disorder history—specifically ask about bulimia/anorexia
3. Inadequate early monitoring—the first 2 weeks are highest risk for suicidality
4. Evening dosing—causes insomnia
5. Combining with other seizure threshold-lowering drugs without careful consideration

Evidence Quality Note

The 2025 ATS guideline for adolescents provides a conditional recommendation with very low-certainty evidence 4, but emphasizes that clinical experience and favorable risk-benefit profile support use. The adult literature is more robust, with multiple RCTs demonstrating efficacy 10, 12.